- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
- 10-K Annual report
- 10.13 EX-10.13
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.20 EX-10.20
- 10.20.1 EX-10.20.1
- 10.20.2 EX-10.20.2
- 10.20.3 EX-10.20.3
- 10.20.4 EX-10.20.4
- 10.20.5 EX-10.20.5
- 10.20.6 EX-10.20.6
- 10.26 EX-10.26
- 21.1 EX-21.1
- 23.1 EX-23.1
- 23.2 EX-23.2
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- Download Excel data file
- View Excel data file
Exhibit 23.2
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-221491) of CRISPR Therapeutics AG, |
| (2) | Registration Statement (Form S-8 No. 333-221427) pertaining to the CRISPR Therapeutics AG Amended and Restated 2016 Stock Option and Incentive Plan (the “Amended Plan”), and |
| (3) | Registration Statement (Form S-8 No. 333-214184) pertaining to the CRISPR Therapeutics AG 2015 Stock Option and Grant Plan, the CRISPR Therapeutics AG 2016 Stock Option and Incentive Plan, the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan, the Non-Qualified Option Agreement with Megan Menner, the Non-Qualified Option Agreement with Paul Schneider, and the Non-Qualified Option Agreement with Pablo Cagnoni of CRISPR Therapeutics AG |
of our report dated March 8, 2018, with respect to the consolidated financial statements of Casebia Therapeutics LLP included in this Annual Report (Form 10-K) of CRISPR Therapeutics AG for the year ended December 31, 2017.
|
| /s/ Ernst & Young LLP |
Boston, Massachusetts |
|
|
March 8, 2018 |
|
|